| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
314.85(M) |
| Last
Volume: |
1,142,525 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
83,136 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
60,500 |
249,935 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,400 |
71,402 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
272,536 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
103,216 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-12-13 |
4 |
AS |
$55.69 |
$4,640,815 |
D/D |
(83,333) |
189,435 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-12-13 |
4 |
OE |
$11.34 |
$944,996 |
D/D |
83,333 |
272,768 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$211,508 |
D/D |
(4,782) |
43,820 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$296,253 |
D/D |
(6,698) |
76,716 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$222,123 |
D/D |
(5,022) |
56,553 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$292,803 |
D/D |
(6,620) |
246,536 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$233,932 |
D/D |
(5,289) |
60,549 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-11-16 |
4 |
D |
$44.23 |
$799,192 |
D/D |
(18,069) |
189,435 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$247,555 |
D/D |
(5,597) |
67,636 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
48,602 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
83,414 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
61,575 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
253,156 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
65,838 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
207,504 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
73,233 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-11-13 |
4 |
AS |
$37.78 |
$601,080 |
D/D |
(15,910) |
233,156 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-11-13 |
4 |
OE |
$9.24 |
$231,000 |
D/D |
25,000 |
249,066 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-11-08 |
4 |
AS |
$30.09 |
$9,027,000 |
D/D |
(300,000) |
31,102 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-11-08 |
4 |
OE |
$9.53 |
$2,859,000 |
D/D |
300,000 |
331,102 |
|
- |
|
709 Records found
|
|
Page 17 of 29 |
|
|
0.05 (2.5%) 
